albumin binding raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-09-07 and is reviewed periodically as new material appears.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
| Property | Value | Notes |
|---|---|---|
| Chemical class | GLP-1 receptor agonist peptide | Mimics endogenous incretin signaling |
| Molecular mass | Approximately 4114 Da | Modified 31-amino-acid backbone |
| Appearance | White to off-white powder | Typical of lyophilized peptide material |
| Solubility | Soluble in water | Behavior depends on salt form and buffer |
| Elimination half-life | About one week | Supported by albumin binding and protease resistance |
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
=== Category:EC 6.2 (form carbon–sulfur bonds) === EC 6.2.1.1: Acetate—CoA ligase EC 6.2.1.2: Medium-chain acyl—CoA ligase EC 6.2.1.3: Long-chain-fatty-acid—CoA ligase EC 6.2.1.4: Succinate—CoA ligase (GDP-forming) EC 6.2.1.5: Succinate—CoA ligase (ADP-forming) EC 6.2.1.6: Glutarate—CoA ligase EC 6.2.1.7: Cholate—CoA ligase EC 6.2.1.8: Oxalate—CoA ligase EC 6.2.1.9: Malate—CoA ligase EC 6.2.1.10: Acid—CoA ligase (GDP-forming) EC 6.2.1.11: Biotin—CoA ligase EC 6.2.1.12: 4-Coumarate—CoA ligase EC 6.2.1.13: Acetate—CoA ligase (ADP-forming) EC 6.2.1.14: 6-carboxyhexanoate—CoA ligase EC 6.2.1.15: Arachidonate—CoA ligase EC 6.2.1.16: Acetoacetate—CoA ligase EC 6.2.1.17: Propionate—CoA ligase EC 6.2.1.18: Citrate—CoA ligase EC 6.2.1.19: Long-chain-fatty-acid-luciferin-component ligase EC 6.2.1.20: Long-chain-fatty-acid-(acyl-carrier-protein) ligase EC 6.2.1.21: Transferred entry: 6.2.1.30 EC 6.2.1.22: (citrate (pro-3S)-lyase) ligase EC 6.2.1.23: Dicarboxylate—CoA ligase EC 6.2.1.24: Phytanate—CoA ligase EC 6.2.1.25: Benzoate—CoA ligase EC 6.2.1.26: o-Succinylbenzoate—CoA ligase EC 6.2.1.27: 4-hydroxybenzoate—CoA ligase EC 6.2.1.28: 3-alpha,7-alpha-dihydroxy-5-beta-cholestanate—CoA ligase EC 6.2.1.29: Transferred entry: 6.2.1.7 EC 6.2.1.30: Phenylacetate—CoA ligase EC 6.2.1.31: 2-furoate—CoA ligase EC 6.2.1.32: Anthranilate—CoA ligase EC 6.2.1.33: 4-chlorobenzoate—CoA ligase EC 6.2.1.34: trans-Feruloyl—CoA synthase EC 6.2.1.35: ACP-SH:acetate ligase EC 6.2.1.36: 3-hydroxypropionyl-CoA synthase EC 6.2.1.37: 3-hydroxybenzoate—CoA ligase EC 6.2.1.38: (2,2,3-trimethyl-5-oxocyclopent-3-enyl)acetyl-CoA synthase EC 6.2.1.39: (butirosin acyl-carrier protein)—L-glutamate ligase EC 6.2.1.40: 4-Hydroxybutyrate—CoA ligase EC 6.2.1.41: 3-((3aS,4S,7aS)-7a-methyl-1,5-dioxo-octahydro-1H-inden-4-yl)propanoate—CoA ligase EC 6.2.1.42: 3-oxocholest-4-en-26-oate—CoA ligase EC 6.2.1.43: 2-hydroxy-7-methoxy-5-methyl-1-naphthoate—CoA ligase EC 6.2.1.44: 3-(methylthio)propionyl—CoA ligase EC 6.2.1.45: E1 ubiquitin-activating enzyme EC 6.2.1.46: L-allo-Isoleucine—holo-CmaA peptidyl-carrier protein ligase EC 6.2.1.47: Medium-chain-fatty-acid-(acyl-carrier-protein) ligase EC 6.2.1.48: Carnitine—CoA ligase EC 6.2.1.49: Long-chain fatty acid adenylyltransferase FadD28 EC 6.2.1.50: 4-hydroxybenzoate adenylyltransferase FadD22 EC 6.2.1.51: 4-hydroxyphenylalkanoate adenylyltransferase FadD29 EC 6.2.1.52: L-Firefly luciferin—CoA ligase EC 6.2.1.53: L-Proline—L-prolyl-carrier protein ligase EC 6.2.1.54: D-Alanine—D-alanyl-carrier protein ligase EC 6.2.1.55: E1 SAMP-activating enzyme
That same day, Peru and the OAS signed a joint declaration in favor of democracy and human rights. The OAS leader Luis Almagro said that "We have seen that president Castillo has much determination to fight corruption, especially corruption that may appear in his government. Let his management be as clean as possible. This requires important efforts in investigation. Let there be a permanent monitoring of transparency, of justice, so that there isn't any element of shadow over official members." On 5 December, Cuarto Poder finally released the audio clip. The audio showed the owner of the Breña house offering "scoops and headlines" to a journalist in exchange for the journalist shelving an unfavorable news story. The host of ATV news, Juliana Oxenford, claimed that it is "much more revealing to know the high content of trans fats in Cheese Tris than the audio of Cuarto Poder." Meanwhile, the journalist Juan Carlos Tafur said that the Cuarto Poder audio "qualifies as a journalistic scam." Following the release of the Cuarto Poder clips, the impeachment motion rapidly fell apart as less hardline members of the opposition rescinded their support for the impeachment motion. On 7 December 2021, with 46 in favor, 76 against, and 4 abstentions, Congress refused to admit the impeachment motion. Following the defeat of the impeachment motion, President Castillo said: "I am grateful that the congressional voted to put Peru first before other interests."
== Personal life == Fenn married Margaret Wilson at the end of his second year of graduate studies. Together, they had three children – two daughters and a son. Margaret was killed in a car accident in New Zealand in 1992. Fenn remarried, his second wife was named Frederica Mullen. He died in Richmond, Virginia on December 10, 2010, at the age of 93, exactly 8 years to the day after receiving his Nobel Prize. Fenn was survived by Frederica, his three children, seven grandchildren, and eleven great-grandchildren: Anika Fenn Gilman, Nora Fenn Gilman, Dominick Brown, Aaron Holloway, Michelle Holloway, Damarion Holloway, Tyrell Holloway, Eloise Whittington, JC Leslie, Manon Leslie, and Dino Steinberg.
Staley met guitarist Jerry Cantrell at a party in Seattle around August 1987. A few months prior, Cantrell had watched a concert of Alice N' Chains in his hometown at the Tacoma Little Theatre, and was impressed by Staley's voice. Cantrell was homeless after being kicked out of his family's house, so Staley invited Cantrell to live with him at the rehearsal studio Music Bank. Alice N' Chains soon disbanded, and Staley joined a funk band. Cantrell's band, Diamond Lie, broke up and he wanted to form a new band, so Staley gave him the phone number of Melinda Starr, the girlfriend of drummer Sean Kinney, so that Cantrell could set up a meeting with Kinney. Kinney and his girlfriend went to the Music Bank and listened to Cantrell's demos, who mentioned that they needed a bass player to jam with them, and he had someone in mind: Mike Starr, Melinda's brother, with whom Cantrell had played in a band in Burien called Gypsy Rose. Kinney mentioned that his girlfriend was actually Mike Starr's sister, and that he had been playing in bands together with Starr since they were kids. Kinney called Starr and a few days later he started jamming with him and Cantrell at the Music Bank. Staley's funk band also required a guitarist at the time, and Staley asked Cantrell to join as a sideman. Cantrell agreed on condition that Staley join his band. Because Cantrell, Starr and Kinney wanted Staley to be their lead singer, they started auditioning terrible lead singers in front of Staley to send a hint. When they auditioned a male stripper, Staley decided to join the band.
=== Oat tempeh === A form of tempeh based on barley and oats instead of soy was developed by scientists at the Swedish Department of Food Science in 2008. It can be produced in climatic regions where it is not possible to grow soybeans.
Sources: en.wikipedia.org
===== Other names in the Western world ===== In the last decades, two new important terminologies emerged. Both are commonly used in the Western world in neoshamanic, recreative or pharmaceutical contexts to address ayahuasca-like substances created without the traditional botanical species, due to it being expensive and/or hard to find in these countries. These concepts are surrounded by some controversies involving ethnobotany, patents, commodification and biopiracy:
A frappé coffee, cold coffee, Greek frappé, or just frappé (Greek: φραπέ, frapé [fraˈpe]) is a Greek iced coffee drink generally made from spray-dried instant coffee, water, sugar, ice and milk. The word is often written frappe (without an accent). The frappé was invented in 1957 in Thessaloniki through experimentation by Dimitris Vakondios, a Nescafe representative. Greek Christos Lenzos (1930–2023), a coffeehouse (1964–2013) owner in Pangrati, has been recognized for his self-made version of Greek frappé coffee. Frappés are among the most popular forms of coffee in Greece and Cyprus and have become a hallmark of postwar outdoor Greek coffee culture.
August Krogh and his wife Marie became interested in insulin upon hearing about it while on an American lecture tour in 1923; they modified their itinerary to meet with insulin discoverers Frederick Banting, John Macleod, Charles Best, and James Collip. August Krogh received permission to produce insulin in Denmark; Krogh and Hans Christian Hagedorn, with funding and facilities support from August Kongsted, began experimenting with means of extracting and purifying insulin from fish and rabbit pancreases. Known as the Insulin Laboratory, the research and production arm was operated as a unit of Kongsted's pharmaceutical company, Løvens Kemiske Fabrik. Kongsted rented a factory in Emdrup, Denmark, in late 1923 to help meet the demand for insulin. The Insulin Laboratory and the factory were spun off into a new company, Nordisk Insulin Laboratorium, in July 1924. The company was founded with an associated foundation and the three men served as the board of directors for both, with the foundation board membership barring them from profiting on the sale of insulin. The foundation and Nordisk Insulin signed articles of association in 1926 and the foundation received tax-exempt status by royal decree in January 1927. In 1925, brothers Harald and Thorvald Pedersen, who were former employees of Nordisk, formed their own company, Novo Terapeutisk Laboratorium. Novo and Nordisk competed until they merged in 1989 to become Novo Nordisk.
== N == NAT – National Cancer Institute (NCI) – National Institute of Allergy and Infectious Diseases (NIAID) – National Institute of Child Health and Human Development (NICHD) – National Institutes of Health (NIH) – National Library of Medicine (NLM) – National Prevention Information Network (NPIN) – natural history study – natural killer cells (NK cells) – NCI – New Drug Application – nebulized – Nef – neoplasm – nephrotoxic – neuralgia – neurological complications of AIDS – neuropathy – neutralization – neutralizing antibody – neutralizing domain – neutropenia – neutrophil – New Drug Application (NDA) – New York Cares – NIAID – NICHD – night sweat – NIH – NK cell – NLM – NNRTI – non-Hodgkin's lymphoma (NHL) – non-nucleoside reverse transcriptase inhibitors (NNRTI) – non-steroidal anti-inflammatory drugs (NSAID) – NRTI – nucleic acid – nucleic acid test – nucleocapsid – nucleoli – nucleoside – nucleoside analog – nucleoside reverse transcriptase inhibitors (NRTI) – nucleotide – nucleotide analogs – nucleus – null cell
2 CoF2 + F2 → 2 CoF3 Industrially, both steps are combined, for example in the manufacture of the Flutec range of fluorocarbons by F2 chemicals Ltd, using a vertical stirred bed reactor, with hydrocarbon introduced at the bottom, and fluorine introduced halfway up the reactor. The fluorocarbon vapor is recovered from the top.
Sources: en.wikipedia.org
Although both ribosome display and mRNA display are in vitro selection methods, mRNA display has some advantage over the ribosome display technology. mRNA display utilizes covalent mRNA-peptide complexes linked through puromycin; whereas, ribosome display utilizes stalled, noncovalent ribosome-mRNA-peptide complexes. For ribosome display, selection stringency is limited to keep ribosome-mRNA-peptide in a complex because of the noncovalent ribosome-mRNA-peptide complexes. This may cause difficulties in reducing background binding during the selection cycle. Also, the peptides under selection in a ribosome display system are attached to an enormous rRNA-protein complex, a ribosome, which has a molecular weight of more than 2,000,000 Da. There might be some unpredictable interaction between the selection target and the ribosome, and this may lead to a loss of potential binders during the selection cycle. In contrast, the puromycin DNA spacer linker used in mRNA display technology is much smaller comparing to a ribosome. This linker may have less chance to interact with an immobilized selection target. Thus, mRNA display technology is more likely to give less biased results.
=== Menopausal hot flashes === In 2013, low-dose paroxetine was approved in the US for the treatment of moderate-to-severe vasomotor symptoms such as hot flashes and night sweats associated with menopause. At the low dose used for menopausal hot flashes, side effects are similar to placebo and dose tapering is not required for discontinuation.
A far-red cyanine dye known as Cy5, which has a peak absorption near 650 nm and emission around 675 nm, allowing detection by imaging systems. A non-fluorescent chromophore called QSY21 (a rhodamine derivative), which functions as a fluorescence quencher. QSY21 absorbs the emission from Cy5, suppressing fluorescence until enzymatic cleavage occurs. A tripeptide linker (Gly-Gly-Arg), which is cleaved by tumor-associated proteases (cathepsins and matrix metalloproteinases). Once cleaved, Cy5 is released from proximity to QSY21, restoring its fluorescence. A polyethylene glycol (PEG) side chain that enhances water solubility, protects the molecule from enzymatic degradation, extends circulation time by increasing its hydrodynamic radius—thereby reducing renal clearance—and lowers immunogenicity.
=== Carbon emissions === Estimates of the carbon footprint of UK AI infrastructure have been subject to significant upward revision. In April 2026, the Department for Science, Innovation and Technology (DSIT) published corrected figures in its Compute Evidence Annex, estimating that UK greenhouse gas emissions from AI compute over the ten years from 2025 to 2035 could range from 34 to 123 MtCO₂. This represents around 0.9% to 3.4% of the UK's projected total emissions over that period. The government noted that these indirect emissions depend heavily on how quickly the UK decarbonises its energy grid; if the plan to have clean sources produce at least 95% of Great Britain's generation by 2030 is successful, emissions would fall towards the bottom of this range. Conversely, some studies suggest that digital substitution can offset physical energy use. A 2025 report by Europe Economics for the Department for Energy Security and Net Zero found that in specific use cases, such as AI-powered translation versus human translation, the digital option either matched or substantially undercut the electricity use of the physical alternative across the full delivery chain.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and cleared quickly. Semaglutide carries a position 8 substitution that blocks that cleavage and a fatty diacid chain that binds albumin. Together these changes extend its circulating half-life to about one week.
Yes. Stimulation of insulin secretion is glucose-dependent, meaning the effect is larger when blood glucose is high and minimal when it is normal. This property separates GLP-1 receptor agonists from agents that drive insulin release regardless of glucose level.
Receptor expression in hypothalamic and brainstem regions is well documented, and reduced energy intake is consistently observed. The relative contribution of central versus peripheral signaling to total weight change is still an open question addressed by ongoing research.
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.